Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran

References

• Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L Randomized evaluation of long-term anticoagulation therapy I. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875–1876.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013.
   Web of Science ®Google Scholar
• Inc BIP. Pradaxa (Dabigatran Etexilate Mesylate) Prescribing Information. 2012.
   Google Scholar
• Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate – A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116–1127.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259–268.
   PubMed Web of Science ®Google Scholar
• Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012; 108:583–585.
   PubMed Web of Science ®Google Scholar
• Esnault P, Gaillard PE, Cotte J, Cungi PJ, Beaume J, Prunet B. Haemodialysis before emergency surgery in a patient treated with dabigatran. Br J Anaesth 2013.
   PubMed Web of Science ®Google Scholar
• Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11:1493–1502.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63:321–328.
   PubMed Web of Science ®Google Scholar
• Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol, 2014.
   Web of Science ®Google Scholar
• Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 2012; 50:854–857.
   PubMed Web of Science ®Google Scholar
• Sipahi I, Celik S, Tozun N. A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med 2014; 174:150–151.
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272–1274.
   PubMed Web of Science ®Google Scholar
• Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS, Winchester JF. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 2013; 62:591–594.
   PubMed Web of Science ®Google Scholar
• Chiew AL, Khamoudes D, Chan BS. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol (Phila) 2014; 52:283–287.
   PubMed Web of Science ®Google Scholar
• Kumar R, Smith RE, Henry BL. A review of and recommendations for the management of patients with life-threatening dabigatran- associated hemorrhage: a single-center university hospital experience. J Intensive Care Med 2014.
   Web of Science ®Google Scholar
• Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013; 61:487–489.
   PubMed Web of Science ®Google Scholar
• Mardini J, Lavergne V, Roberts D, Ghannoum M. Case reports of extracorporeal treatments in poisoning: historical trends. Semin Dial 2014; 27:402–406.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Nolin TD. What is the role of renal replacement therapy in the setting of dabigatran toxicity? Semin Dial 2014; 27:223–226.
   PubMed Web of Science ®Google Scholar
• Lavergne V, Nolin TD, Hoffman RS, Robert D, Gosselin S, Goldfarb DS, et al. The EXTRIP (Extracorporeal Treatments In Poisoning) workgroup: guideline methodology. Clin Toxicol 2012; 50:403–413.
   PubMed Web of Science ®Google Scholar
• Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21:612–620.
   PubMed Web of Science ®Google Scholar
• Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009; 64:929–937.
   PubMed Web of Science ®Google Scholar
• Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial 2014; 27:407–414.
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386–399.
   PubMed Web of Science ®Google Scholar
• Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121:3554–3562.
   PubMed Web of Science ®Google Scholar
• Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease . Thromb Haemost, 2013; 109.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Goralski KB, Soroka SD, Morrison M, Mossop P, Sleno L, et al. An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol 2014.
   PubMed Web of Science ®Google Scholar
• Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012; 10:160–163.
   PubMed Web of Science ®Google Scholar
• Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 2012; 46:e18.
   PubMedGoogle Scholar
• Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract 2012.
   PubMed Web of Science ®Google Scholar
• Kulik A, Saltzman MB, Morris JJ. Dabigatran after cardiac surgery: caution advised. J Thorac Cardiovasc Surg 2011; 142:1288.
   PubMed Web of Science ®Google Scholar
• Liesenfeld KH, Lehr T, Moschetti V, Formella S, Clemens A, Staab A, et al. Modelling and simulation of redistribution of dabigatran after elimination by hemodialysis in patients with end stage renal disease. J Thromb Haemost 2011; 9:597–598.
   Web of Science ®Google Scholar
• Liesenfeld KH, Staab A, Hartter S, Formella S, Clemens A, Lehr T. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013.
   PubMed Web of Science ®Google Scholar
• Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012; 46:e21.
   Google Scholar
• Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172–2174.
   PubMed Web of Science ®Google Scholar
• Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46:e10.
   PubMedGoogle Scholar
• Kamboj J, Kottalgi M, Cirra VR, Shah N, Kamboj R. Direct thrombin inhibitors-a case indicating benefit from ‘plasmapheresis’ in toxicity: a call for establishing ‘gUIDELINES’ in overdose and to find an ‘aNTIDOTE’! Am J Ther 2012; 19:e182–e185.
   PubMedGoogle Scholar
• Verma A, Nathan R, Abramov K, Trainor MJ, Stoff JS. Role of dialysis in dabigatran related bleeding. ASN, San Diego; 2012.
   Google Scholar
• Bouchard J, Roberts DM, Roy L, Ouellet G, Decker BS, Mueller BA, et al. Principles and operational parameters to optimize poison removal with extracorporeal treatments. Semin Dial 2014.
   Web of Science ®Google Scholar
• Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet 2007; 46:897–939.
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285–295.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292–303.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126:2428–2432.
   PubMed Web of Science ®Google Scholar
• Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121:4032–4035.
   PubMed Web of Science ®Google Scholar
• Ronco C, Bellomo R, Brendolan A, Pinna V, La Greca G. Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. J Nephrol 1999; 12:173–178.
   Google Scholar
• Lin CM, Lin JW, Tsai JT, Ko CP, Hung KS, Hung CC, et al. Intracranial pressure fluctuation during hemodialysis in renal failure patients with intracranial hemorrhage. Acta Neurochir Suppl 2008; 101:141–144.
   PubMedGoogle Scholar